What is Intest's latest dividend and current dividend yield?

What guidance did Intest's management provide for the next earnings period?

What factors drove the changes in Intest's revenue and profit?

Did Intest beat or miss consensus estimates last quarter?

What does Intest do and what are its main business segments?

What is Intest's gross profit margin?

What is the market's earnings forecast for Intest next quarter?

What is the revenue and EPS growth rate for Intest year over year?

- **Revenue Growth**: Q4 2025 revenue $32.8M (+25% QoQ, +36% YoY backlog), 80% from non-semi markets.
- **Margin Expansion**: 45.4% gross margin driven by new products, 2026 guidance for 45% margin.
- **Diversified Growth**: 2026 revenue $125-130M (+12%), Life Sciences orders +137% YoY, Auto EV +89% YoY.
- **Semi Cautiousness**: Modest recovery in 2026, back-end test positioning for upside.
- **Cash Position**: $58M liquidity, debt reduction to $7.5M, well-positioned for growth.

**【CEO Summary Section】**
- Q4 2025 revenue of $32.8 million, up 25% sequentially and 36% year-over-year backlog growth to $53.9 million.
- Non-semiconductor revenue now 80% of Q4, with Life Sciences orders tripling sequentially and Auto EV orders up 89% YoY.
- Gross margin of 45.4% achieved without semi contribution, driven by new products (e.g., Alfamation) and manufacturing efficiency.
- 2026 guidance: $125-130 million revenue, 45% gross margin, reflecting diversified growth and new product adoption.

**【CFO Financial Commentary】**
- Q4 GAAP net income $1.2 million, adjusted EBITDA $3.2 million (9.7% margin).
- Full year 2025 adjusted EBITDA $4 million vs. $10.8 million in 2024, due to semi weakness.
- 2026 Q1 guidance: $31-33 million revenue, 44% gross margin, $13.3-13.7 million operating expenses.
- Full year 2026: 12% revenue growth, 45% gross margin, $53-55 million operating expenses.

**【Q&A Highlights】**
- **Semi Market**: Cautious outlook with modest recovery baked into 2026 guidance; back-end test positioning for potential upside.
- **Automotive**: 2027 model year programs driving Q4 orders, Alfamation well-positioned for EV test equipment growth.
- **Life Sciences**: MedTech testing adoption (e.g., glucometers) driving triple-digit order growth, low penetration rate for expansion.
- **Gross Margin**: 45.4% Q4 margin reflects new product mix; semi recovery could push margins higher, but not guaranteed.
- **2026 Cadence**: Sequential growth expected, with semi recovery potential in H2.

inTEST Corporation(INTT)-20260227-2025 Q4 Earnings call transcript

**Key Takeaways**
- **Revenue Recovery Signs**: Q3 orders jump 42% YoY to $37.6 million, with automotive and defense/aerospace leading. Backlog surges to $49.3 million, positioning for Q4 rebound to $30-32 million.
- **New Product Success**: Acculogic's RF probes win multiple orders, Alfamation's life sciences bookings hit record levels. Innovation driving growth in new markets.
- **Challenges Resolved**: $2 million in delayed shipments resolved, with customers satisfied and follow-on orders secured.
- **Financial Strength**: $21.1 million cash, $61 million liquidity. Operating expenses down 5.6% YoY, with $500k annual savings from facility consolidation.
- **Market Outlook**: Gradual recovery expected, with automotive programs extending into 2027. Semi market cautious, but long-term optimism for 2026-2027.

**【CEO Summary Section】**
- **Revenue and Orders**: Q3 revenue of $26.2 million, down 6.8% sequentially due to $2 million in delayed shipments. Orders surged 42% YoY to $37.6 million, the highest since Q2 2022, with a 34.2% YoY increase driven by automotive (up $7.4 million) and defense/aerospace (up $1.9 million). Backlog rose to $49.3 million, up $11.4 million sequentially.
- **Market Performance**: Automotive/EV orders doubled to $14.6 million, defense/aerospace orders more than doubled to $6.4 million. Semi remained sluggish, but Alfamation (life sciences) bookings hit an all-time high. New product innovations, like Acculogic's RF and oscilloscope probes, won multiple orders from new customers.
- **Challenges and Wins**: Technical delays in two systems (life sciences and semi) caused Q3 revenue miss, but issues resolved, and tools shipped. Customer satisfaction high, with Alfamation receiving LOI for additional systems.
- **Strategy**: Focused on market diversification, new customer penetration, and VISION 2030 goals. Strong funnel suggests gradual recovery, but semi hesitancy persists.

**【CFO Financial Commentary】**
- **Financials**: Q3 GAAP net loss of $0.9 million (-$0.08 EPS), with adjusted EBITDA of $0.4 million. Gross margin 41.9%, down 70 bps sequentially due to lower volume. Operating expenses decreased $0.7 million sequentially to $12.2 million, benefiting from $500k annualized savings from Videology facility consolidation.
- **Liquidity**: $21.1 million cash, $61 million liquidity. Debt reduced $6.2 million year-to-date, ending at $8.9 million with 1.7x leverage ratio.
- **Guidance**: Q4 revenue expected $30-32 million (up 14-22% from Q3), driven by $2 million in delayed shipments and backlog conversion. Gross margin ~43%, operating expenses $12.3-12.7 million.

**【Q&A Highlights】**
- **Slippage Details**: $1.5 million from life sciences (Alfamation delays), $0.5 million from semi (Acculogic RF probe delays). Both resolved, with customer satisfaction.
- **Automotive Momentum**: 2027 model year programs driving demand, with healthy funnel for future orders. Test equipment investments for infotainment, CCUs, and lighting expected to continue.
- **Semi Market**: Front-end activity anemic, back-end softer due to tariff uncertainty. Long-term optimism for 2026-2027, but near-term sluggishness persists.
- **Industrial Segment**: Stable with book-to-bill >1 for 5 of last 6 quarters, but growth constrained by cautious customer CapEx.
- **Guidance Context**: Q4 range reflects cautious execution, with upside potential from backlog. Teams focused on minimizing risks, with confidence in long-term recovery.

inTEST Corporation (INTT) Q3 2025 Earnings Call Transcript

- **Revenue Resilience**: $28.1 million Q2 revenue with 10% sequential growth, driven by auto/EV (+40%), life sciences (+100%), and defense/aero (+27%).
- **Margin Expansion**: Gross margin improved to 42.6%, up 110bps sequentially, supported by cost reductions and tariff mitigation.
- **Debt Reduction**: $1.7 million Q2 debt reduction, total debt down to $10.1 million, with $5 million year-to-date reduction.
- **Strategic Expansion**: Malaysia facility to begin production in H2 2025, targeting $10-15 million annual revenue by 2026, enhancing Asian market competitiveness.
- **Defense Momentum**: $2.5 million defense/aero orders in Q2, with Q3 order already booked, signaling diversification success.
- **OpEx Control**: $1 million Q2 savings through headcount reduction (50+ positions Y/Y) and austerity measures, with 2026 savings from Videology consolidation.

**【CEO Summary Section】**
- Q2 2025 revenue of $28.1 million, with orders of $28 million, reflecting 10% sequential growth driven by auto/EV (+40%), life sciences (+100%), and defense/aero (+27%).
- Gross margin improved to 42.6%, up 110bps sequentially, due to cost reductions and tariff mitigation.
- Debt reduced by $1.7 million to $10.1 million, with $5 million year-to-date reduction.
- Malaysia facility expansion on track to begin production in H2 2025, targeting $10-15 million annual revenue by 2026.
- Defense/aero order of $2.5 million highlights diversification success, with auto/EV orders up 40% for 2027 model year programs.
- Customer pipeline at all-time high, with new products (20% of Q2 sales) driving innovation and VISION 2030 goals.

**【CFO Financial Commentary】**
- Q2 net loss of $0.5 million (-$0.04 EPS) vs. adjusted net earnings of $0.4 million (+$0.03 EPS), with adjusted EBITDA of $1.3 million.
- Operating expenses down $1 million sequentially to $12.9 million, driven by headcount reduction (50+ positions Y/Y) and austerity measures.
- $500k annualized savings from Videology facility consolidation to begin in 2026.
- Q3 2025 guidance: $28-30 million revenue, gross margin similar to Q2, OpEx $12.6-13.1 million.

**【Q&A Key Highlights】**
- **Defense Order**: Follow-on from existing customer, part of $2.5 million defense/aero orders in Q2, with Q3 order already booked.
- **Order Pattern**: Strong start to Q3 with auto/EV and defense activity, though semi remains weak.
- **Malaysia Capacity**: Expected to generate $10-15 million annual revenue over time, supporting Asian market competitiveness.
- **Semi Outlook**: Front-end recovery likely in 2026, back-end semi softness persists.
- **OpEx Management**: $1 million Q2 savings temporary (travel, marketing cuts), with 50+ headcount reductions Y/Y. Savings from Videology consolidation to materialize in 2026.
- **Life Sciences Growth**: Alfamation's $2.9 million life sciences orders reflect diversification success, with pipeline for follow-on business.


inTEST Corporation (INTT) Q2 2025 Earnings Call Transcript

- **Revenue resilience amid challenges**: $26.6M Q1 revenue with $5.5M cash flow, despite $1.5M shipment delays. Auto/EV and life sciences offset semi decline.
- **Cost control success**: Debt reduced by $3.2M, cash position at $22M. Q2 targets $27-29M revenue with 42% gross margin.
- **Long-term growth drivers**: Malaysia manufacturing to start H2 2025, new products at 17% of sales (target 25% by 2030). Opportunity funnel at all-time high.

**【CEO Summary Section】**
- Q1 2025 revenue of $26.6 million, down 11% sequentially due to $1.5 million in delayed shipments from engineering challenges. Gross margin of 41.5%.
- Auto/EV sales grew $2 million, life sciences $1 million, offsetting semi and industrial declines. Backlog at $38.2 million, stable excluding Alfamation.
- Implemented cost controls: reduced debt by $3.2 million, restricted hiring, and utilized wage subsidies. Malaysia manufacturing to begin H2 2025.

**【CFO Financial Commentary】**
- Q1 GAAP net loss of $2.3 million (-$0.19 EPS), adjusted EBITDA negative $0.9 million. Sequential cash generation of $5.5 million, debt reduced to $11.8 million.
- Q2 guidance: $27-29 million revenue, 42% gross margin, $13-13.5 million operating expenses. Cost structure adjustments aim for breakeven near $27 million.

**【Q&A Key Highlights】**
- Order delays began mid-quarter, driven by tariff uncertainty and customer caution. Semi and auto/EV are key swing factors.
- Industrial growth from $1.5 million utility pole induction heating systems. Engineering delays resolved; shipments expected in weeks.
- Opportunity funnel at record high, but visibility limited by macroeconomic conditions.
- Malaysia facility to reduce supply chain and logistics costs, enhancing competitiveness.

inTEST (INTT)-2 May 25-2025 Q1 Earnings call transcript

- **Record Revenue Growth**: Q4 2024 revenue of $36.6M (YoY +8.7%) and full-year 2024 record of $130.7M, driven by Auto EV and Defense/Aero market expansion.
- **Acquisition Impact**: Affirmation acquisition contributed $25M to 2024 revenue, with $8.5M in Q4 sales.
- **Gross Margin Challenge**: Q4 gross margin of 39.7% (-490bps YoY) due to $1.6M inventory step-up charge.
- **2025 Outlook**: Cautious guidance of $125-135M revenue, with Q1 at $27-29M and 41% gross margin.
- **Key Risks**: Semi market weakness, tariff-related order delays, and industrial market softness.
- **Strategic Moves**: Middle East manufacturing expansion, Videology facility consolidation ($500K annual savings), and renewed stock buyback plan.
- **Long-Term Ambition**: 2030 vision of $200M+ revenue, with focus on silicon carbide, induction heating, and defense aerospace solutions.

**【CEO Opening Remarks】**
- Q4 2024 revenue: $36.6M (YoY +8.7%), full-year 2024 revenue: $130.7M (YoY +6%), driven by $25M contribution from Affirmation acquisition and growth in Auto EV, Defense/Aero, and Life Sciences markets.
- Auto EV revenue growth fueled by Alfamation's infotainment system testing tech and battery pack testing solutions, with repeat orders and a regained customer.
- Defense/Aero market record sales ($2.3M in Q4 orders) driven by innovative environmental and test technologies for primes, space companies, and NASA.
- Semi market decline (-26% YoY) offset by diversification strategy; Back-end semi improvement (+$2.4M Q4 orders) offset front-end weakness.
- Gross margin impacted by $1.6M inventory step-up charge from Affirmation acquisition.
- 2025 outlook cautious: $125-135M revenue, with Q1 guidance of $27-29M and gross margin ~41%.

**【CFO Financial Details】**
- Q4 2024 GAAP net income: $1.5M ($0.12 EPS), adjusted net income: $2.8M ($0.23 EPS).
- Adjusted EBITDA: $4.4M (12.1% margin), including $1.6M inventory step-up impact.
- Operating expenses: $12.5M (YoY +1.1%), driven by Affirmation costs offset by core business cost-cutting.
- Cash flow: $2.6M from operations, ending with $19.8M cash and $15M debt (1.4x leverage).
- 2025 capital expenditures: 1-2% of revenue; amortization: $3.4M.

**【Q&A Key Takeaways】**
- **Order Pushouts**: $3M of Q1 backlog delayed to H2 2025 due to customer uncertainty; no cancellations reported.
- **Life Sciences Growth**: Q4 orders up 122% YoY ($2.3M) driven by induction heating solutions and medical applications.
- **Market Trends**: 
  - Front-end semi paused until 2026; back-end semi showing pockets of improvement.
  - Auto EV demand softening; industrial markets impacted by tariff uncertainty.
  - Defense/Aero pipeline strong, with new channel partner in Japan.
- **M&A Strategy**: Actively pursuing deals, with focus on valuation timing and strategic fit.
- **Long-Term Vision**: 2030 target of $200M+ revenue remains intact; Middle East manufacturing expansion to reduce supply chain costs.


Actual											-0.08	0.05	0.07	-0.01	0.24	0.27	0.23	0.07	0.12	0.25	0.28	0.34	0.29	0.28	0.28	0.16	0.1	0.08	0.1	0.23	-0.11	0.03	-0.02	0.16
Forecast											-0.0867	-0.0267	0.0567	-0.0333	0.225	0.25	0.225	0.11	0.11	0.21	0.28	0.32	0.2767	0.25	0.255	0.135	0.09	0.14	0.065	0.14	-0.1033	-0.0333	0.0433	0.11
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+7.73%	+287.27%	+23.46%	+69.97%	+6.67%	+8.00%	+2.22%	-36.36%	+9.09%	+19.05%	0.00%	+6.25%	+4.81%	+12.00%	+9.80%	+18.52%	+11.11%	-42.86%	+53.85%	+64.29%	-6.49%	+190.09%	-146.19%	+45.45%

INTT

INTT fundamentals

INTT Q4 2025 Earnings

Earnings Call

You can ask Aime

INTT

INTT fundamentals

INTT Q4 2025 Earnings

Earnings Call

INTT Earnings Call Summary for Q4/20258:30 AM on Feb 27, 2026

INTT Earnings Call Summary for Q3/20258:30 AM on Nov 5, 2025

INTT Earnings Call Summary for Q2/20258:30 AM on Aug 6, 2025

INTT Earnings Call Summary for Q1/20258:30 AM on May 2, 2025

INTT Earnings Call Summary for Q4/20248:30 AM on Mar 7, 2025

You can ask Aime